The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis
Breast cancer is the most common cancer in women and the second leading cause of female cancer-related deaths worldwide. Inflammation is an established hallmark of tumorigenesis and an important determinant of tumor outcome and response to therapy. With advances in cancer immunotherapy, there is an...
Main Authors: | Maryse Dagenais, Jeremy Dupaul-Chicoine, Todd Douglas, Claudia Champagne, Alexandre Morizot, Maya Saleh |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-03-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1287247 |
Similar Items
-
The Role of Interleukin 1β in the Pathogenesis of Lung Cancer
by: Edward B. Garon, MD, et al.
Published: (2020-03-01) -
Interleukin-1β and Cancer
by: Cédric Rébé, et al.
Published: (2020-07-01) -
Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases
by: Gabriele Fenini, et al.
Published: (2017-05-01) -
Apc mutation enhances PyMT-induced mammary tumorigenesis.
by: Jenifer R Prosperi, et al.
Published: (2011-01-01) -
Role of Caspase-1 in the Pathogenesis of Inflammatory-Associated Chronic Noncommunicable Diseases
by: Molla MD, et al.
Published: (2020-10-01)